CN104945375B - 7‑{(3s,4s)‑3‑[(环丙基氨基)甲基]‑4‑氟吡咯烷‑1‑基}‑6‑氟‑1‑(2‑氟乙基)‑8‑甲氧基‑4‑氧‑1,4‑二氢喹啉‑3‑羧酸晶体 - Google Patents

7‑{(3s,4s)‑3‑[(环丙基氨基)甲基]‑4‑氟吡咯烷‑1‑基}‑6‑氟‑1‑(2‑氟乙基)‑8‑甲氧基‑4‑氧‑1,4‑二氢喹啉‑3‑羧酸晶体 Download PDF

Info

Publication number
CN104945375B
CN104945375B CN201510329284.3A CN201510329284A CN104945375B CN 104945375 B CN104945375 B CN 104945375B CN 201510329284 A CN201510329284 A CN 201510329284A CN 104945375 B CN104945375 B CN 104945375B
Authority
CN
China
Prior art keywords
crystal
crystals
methyl
compound
cyclopropylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510329284.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104945375A (zh
Inventor
荒谷郎
荒谷一郎
后藤晃范
皆川渡
船田惠子
长尾宗树
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinglin Pharmaceutical Holdings Co ltd
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104945375(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Publication of CN104945375A publication Critical patent/CN104945375A/zh
Application granted granted Critical
Publication of CN104945375B publication Critical patent/CN104945375B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201510329284.3A 2011-11-10 2012-11-09 7‑{(3s,4s)‑3‑[(环丙基氨基)甲基]‑4‑氟吡咯烷‑1‑基}‑6‑氟‑1‑(2‑氟乙基)‑8‑甲氧基‑4‑氧‑1,4‑二氢喹啉‑3‑羧酸晶体 Active CN104945375B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2011-246209 2011-11-10
JP2011246209 2011-11-10
JP2012-071739 2012-03-27
JP2012071739 2012-03-27
CN201280055120.0A CN103930414B (zh) 2011-11-10 2012-11-09 7-{(3s,4s)-3-[(环丙基氨基)甲基]-4-氟吡咯烷-1-基}-6-氟-1-(2-氟乙基)-8-甲氧基-4-氧-1,4-二氢喹啉-3-羧酸晶体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280055120.0A Division CN103930414B (zh) 2011-11-10 2012-11-09 7-{(3s,4s)-3-[(环丙基氨基)甲基]-4-氟吡咯烷-1-基}-6-氟-1-(2-氟乙基)-8-甲氧基-4-氧-1,4-二氢喹啉-3-羧酸晶体

Publications (2)

Publication Number Publication Date
CN104945375A CN104945375A (zh) 2015-09-30
CN104945375B true CN104945375B (zh) 2017-07-04

Family

ID=48289529

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510329284.3A Active CN104945375B (zh) 2011-11-10 2012-11-09 7‑{(3s,4s)‑3‑[(环丙基氨基)甲基]‑4‑氟吡咯烷‑1‑基}‑6‑氟‑1‑(2‑氟乙基)‑8‑甲氧基‑4‑氧‑1,4‑二氢喹啉‑3‑羧酸晶体
CN201280055120.0A Active CN103930414B (zh) 2011-11-10 2012-11-09 7-{(3s,4s)-3-[(环丙基氨基)甲基]-4-氟吡咯烷-1-基}-6-氟-1-(2-氟乙基)-8-甲氧基-4-氧-1,4-二氢喹啉-3-羧酸晶体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280055120.0A Active CN103930414B (zh) 2011-11-10 2012-11-09 7-{(3s,4s)-3-[(环丙基氨基)甲基]-4-氟吡咯烷-1-基}-6-氟-1-(2-氟乙基)-8-甲氧基-4-氧-1,4-二氢喹啉-3-羧酸晶体

Country Status (17)

Country Link
US (3) US9090587B2 (enExample)
EP (2) EP3112359B1 (enExample)
JP (4) JP5871948B2 (enExample)
KR (2) KR20140098074A (enExample)
CN (2) CN104945375B (enExample)
AU (1) AU2016273899B2 (enExample)
BR (1) BR112014010765B1 (enExample)
CA (1) CA2855022C (enExample)
ES (2) ES2621664T3 (enExample)
IN (1) IN2014DN03277A (enExample)
MX (1) MX375073B (enExample)
NZ (1) NZ623808A (enExample)
RU (2) RU2017109814A (enExample)
SA (1) SA112330992B1 (enExample)
SG (2) SG10201608167UA (enExample)
TW (1) TWI547492B (enExample)
WO (1) WO2013069297A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
CA2910121A1 (en) * 2013-04-25 2014-10-30 Kyorin Pharmaceutical Co., Ltd. A pharmaceutical composition comprising a 1,4-dihydroquinoline carboxylic acid a cellulosic excipient and a salting-out agent
WO2014174848A1 (ja) * 2013-04-25 2014-10-30 杏林製薬株式会社 錠剤
CA2910112C (en) * 2013-04-25 2021-02-16 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US10154993B2 (en) * 2014-10-23 2018-12-18 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
WO2016063544A1 (ja) * 2014-10-23 2016-04-28 杏林製薬株式会社 固形医薬組成物
MY191848A (en) * 2015-03-13 2022-07-18 Kyorin Seiyaku Kk Respiratory infection treating agent
US10206917B2 (en) * 2015-06-02 2019-02-19 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
US10406149B2 (en) 2015-06-02 2019-09-10 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid formulation
EP3305294A4 (en) * 2015-06-02 2019-02-20 Kyorin Pharmaceutical Co., Ltd. AQUEOUS MEDICINE
AU2018283234A1 (en) 2017-06-16 2019-12-12 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess
KR20240096794A (ko) * 2017-06-16 2024-06-26 교린 세이야꾸 가부시키 가이샤 흡인성 폐렴, 폐화농증 또는 폐농양의 치료제
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1158846A (zh) * 1995-05-09 1997-09-10 昆山市康壮达兽药厂 盐酸氟哌酸的合成工艺
CN1849316A (zh) * 2003-09-10 2006-10-18 杏林制药株式会社 7－(4－取代－3－环丙基氨基甲基－1－吡咯烷基)喹诺酮羧酸衍生物
CN101003540A (zh) * 2006-01-18 2007-07-25 广州白云山制药股份有限公司广州白云山制药总厂 一种抗感染化合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA944369B (en) * 1993-08-27 1995-02-13 Hokuriku Seuyaku Co Ltd 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative
EP1425577A4 (en) 2001-08-10 2004-12-29 Symyx Technologies Inc APPARATUSES AND METHODS FOR PREPARING AND TESTING PRE-FORMULATIONS AND CORRESPONDING SYSTEMS
WO2003076428A1 (en) * 2002-03-08 2003-09-18 Daiichi Pharmaceutical Co., Ltd. Quinolonecarboxylic acid derivative
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1158846A (zh) * 1995-05-09 1997-09-10 昆山市康壮达兽药厂 盐酸氟哌酸的合成工艺
CN1849316A (zh) * 2003-09-10 2006-10-18 杏林制药株式会社 7－(4－取代－3－环丙基氨基甲基－1－吡咯烷基)喹诺酮羧酸衍生物
CN101003540A (zh) * 2006-01-18 2007-07-25 广州白云山制药股份有限公司广州白云山制药总厂 一种抗感染化合物和用途

Also Published As

Publication number Publication date
NZ623808A (en) 2015-07-31
JPWO2013069297A1 (ja) 2015-04-02
US20140288310A1 (en) 2014-09-25
AU2016273899A1 (en) 2017-01-12
IN2014DN03277A (enExample) 2015-05-22
RU2615509C2 (ru) 2017-04-05
MX375073B (es) 2025-03-06
CN103930414A (zh) 2014-07-16
KR102162208B1 (ko) 2020-10-06
KR20190065456A (ko) 2019-06-11
RU2014123567A (ru) 2015-12-20
RU2017109814A (ru) 2019-01-23
SG11201401817TA (en) 2014-08-28
AU2012337206B2 (en) 2016-09-15
USRE47785E1 (en) 2019-12-31
SA112330992B1 (ar) 2015-09-13
JP6514069B2 (ja) 2019-05-15
JP2017160243A (ja) 2017-09-14
BR112014010765B1 (pt) 2020-07-14
TW201332991A (zh) 2013-08-16
WO2013069297A1 (ja) 2013-05-16
ES2747303T3 (es) 2020-03-10
JP2018158949A (ja) 2018-10-11
JP5871948B2 (ja) 2016-03-01
EP3112359B1 (en) 2019-08-21
EP2778159A4 (en) 2015-06-03
US9328089B2 (en) 2016-05-03
JP6818719B2 (ja) 2021-01-20
US20150284361A1 (en) 2015-10-08
BR112014010765A2 (pt) 2017-06-13
SG10201608167UA (en) 2016-11-29
RU2017109814A3 (enExample) 2020-04-08
TWI547492B (zh) 2016-09-01
CA2855022C (en) 2019-05-07
CN103930414B (zh) 2016-01-20
US9090587B2 (en) 2015-07-28
JP6349435B2 (ja) 2018-06-27
KR20140098074A (ko) 2014-08-07
AU2012337206A8 (en) 2016-09-22
EP2778159A1 (en) 2014-09-17
AU2012337206A1 (en) 2014-05-22
EP2778159B1 (en) 2017-03-01
EP3112359A1 (en) 2017-01-04
AU2016273899B2 (en) 2017-07-27
CN104945375A (zh) 2015-09-30
ES2621664T3 (es) 2017-07-04
JP2016027045A (ja) 2016-02-18
CA2855022A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
CN104945375B (zh) 7‑{(3s,4s)‑3‑[(环丙基氨基)甲基]‑4‑氟吡咯烷‑1‑基}‑6‑氟‑1‑(2‑氟乙基)‑8‑甲氧基‑4‑氧‑1,4‑二氢喹啉‑3‑羧酸晶体
CN114728899A (zh) 新型三苯基化合物盐
AU2015330554B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
KR20170078710A (ko) Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법
EP3710425A1 (en) Solid state forms of elafibranor
AU2012337206B8 (en) 7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal
MX2014005007A (es) Cristal del acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluorop irrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidr oquinolin-3-carboxilico.
HK40076742B (zh) 新型三苯基化合物盐
WO2018054359A1 (zh) 一种喹唑啉衍生物的盐、其制备方法及应用
EP3052499A1 (en) Crystalline abacavir hydrochloride monohydrate and process for its preparation
HK1210080A1 (en) Sulfate of 5-hydroxy-1h-imidazole-4-carboxamide

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Tokyo, Japan

Patentee after: KYORIN PHARMACEUTICAL Co.,Ltd.

Country or region after: Japan

Address before: Tokyo, Japan

Patentee before: Xinglin Pharmaceutical Holdings Co.,Ltd.

Country or region before: Japan

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240301

Address after: Tokyo, Japan

Patentee after: Xinglin Pharmaceutical Holdings Co.,Ltd.

Country or region after: Japan

Address before: Tokyo

Patentee before: KYORIN PHARMACEUTICAL Co.,Ltd.

Country or region before: Japan